tert-butyl (1S,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl (1S,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
• 化学式: C₁₁H₂₀N₂O₂
• 分子量: 212.29
• InChiKey: HNINFCBLGHCFOJ-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Mutant IDH1 inhibitors useful for treating cancer
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE

  公开号：US10703746B2

  公开（公告）日：2020-07-07

  Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

  公开了式 I 和式 II 的化合物及其药学上可接受的盐 本文公开了变量 A、B、Y、Z、X1、X2、R1-4 和 R13-18。这些化合物可用于治疗癌症疾病，特别是涉及突变 IDH1 酶的疾病。还公开了含有式 I 或式 II 化合物的药物组合物以及包括施用式 I 和式 II 化合物的治疗方法。
• Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：US10836759B2

  公开（公告）日：2020-11-17

  A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.

  一种式 II 的化合物或其药学上可接受的盐，其中 CyN 是通过氮原子结合的环胺基；X 是 C 或 N；R1 和 R2 各自独立地是卤素、CN、CF3、CHF2、CH2F、C1-C10 烷基、C1-C10 烷氧基、二(C1-C5 烷基)氨基；m和n各自独立地为1、2或3，代表单键或双键，其中不包括3-(4-(4-氯苯基)噻唑-2-基)-1-(2-乙基-5-甲氧基苯基)-6-(2-甲基丙-1-烯-1-基)-5-(哌嗪-1-羰基)吡啶-2(1H)-酮异构体的外消旋混合物。
• EP3475276B1
  申请人：——

  公开号：EP3475276B1

  公开（公告）日：2021-03-31
• NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3814347A1

  公开（公告）日：2021-05-05
• THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER
  申请人：THE UNITED STATED OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE

  公开号：US20190241551A1

  公开（公告）日：2019-08-08

  A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R 1 and R 2 are each independently a halogen, CN, CF 3 , CHF 2 , CH 2 F, a C 1 -C10alkyl group, a C1-C 10 alkoxy group, a di(C 1 -C 5 alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.